CheckMate-066 established that nivolumab was superior to dacarbazine in previously untreated, BRAF-wild-type melanoma, reporting five-year OS of 39% versus 17%, mainly in cutaneous cases [16]. This evidence concerns the gene BRAF and melanoma.